Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXFOCY: Extended Fosfomycin for Uncomplicated Cystitis
NCT05254808Phase 3Terminated
- Start
- Sep 2021
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of fosfomycin in cystitis (3 arms). Primary endpoint: Days of absence of cystitis symptoms at 28 days. Started Sep 2021; status: terminated.
02
Drugs
fosfomycin
03
Conditions
cystitis
Beyond the preview
Go deeper on NCT05254808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05254808.